BIOCHEMICAL AND BIOLOGICAL ASPECTS OF THE PLASMINOGEN ACTIVATION SYSTEM

被引:171
作者
MAYER, M
机构
[1] Department of Clinical Biochemistry, Hadassah Medical Center, Hadassah-Hebrew University Medical School, Jerusalem, IL-91120
关键词
diabetes mellitus; extracellular matrix; fibrin; fibrinogen; fibrinolysis; fibrinolytic agents; inhibitor; neoplasia; plasmin; plasminogen; plasminogen activator; plasminogen activators; receptors; rheumatoid arthritis; thrombolysis; tissue type; urokinase; urokinase type;
D O I
10.1016/0009-9120(90)90601-P
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Plasminogen activators (PAs) are specific proteolytic enzymes which convert the inactive proenzyme plasminogen to plasmin. The plasmin formed is a potent and nonspecific protease which cleaves blood fibrin clots and several other extracellular proteins. In addition to their primary role in the initiation of fibrinolysis, PAs are implicated in a variety of basic biological processes, such as, degradation of the extracellular matrix, tumor invasiveness, tissue remodelling, and cellular differentiation. This review describes recent observations on the biochemical and biophysical characteristics of the different components of the plasminogen activation system. This complex system includes: the proenzymes of tissue type PA (tPA) and urokinase type PA (uPA); the active enzymes tPA, uPA and plasmin; the substrate plasminogen; several natural inhibitors of PA and plasmin activity; and the cellular receptors that bind the proenzymes, enzymes, and inhibitor-enzyme complexes. Through the coordinated interactions of these components, the location, timing, and extent of potent proteolytic activity is controlled. Recent findings on the structure, properties, biological functions, and regulation of the different components of the plasminogen activation cascade are reviewed. Current methods for assay of the amount and activity of the enzymes, inhibitors, and receptors are described. Observations implying specific functions of the system in health and disease, and its potential utilization for diagnosis are examined. Specifically, the potential application of PAs as laboratory markers of neoplasia, as diagnostic tools in diseases of the blood clotting system, their use for monitoring of thrombolytic therapy, and their possible relevance in certain disease states are described. © 1990 The Canadian Society of Clinical Chemists.
引用
收藏
页码:197 / 211
页数:15
相关论文
共 185 条
  • [1] ALLEN RA, 1982, THROMB HAEMOSTASIS, V47, P41
  • [2] FIBRINOLYTIC-ACTIVITY, AUTONOMIC NEUROPATHY, AND CIRCULATION IN DIABETES-MELLITUS
    ALMER, LO
    SUNDKVIST, G
    LILJA, B
    [J]. DIABETES, 1983, 32 : 4 - 7
  • [3] ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644
  • [4] HORMONAL-REGULATION OF EXTRACELLULAR PLASMINOGEN ACTIVATORS AND MR - 54000 PLASMINOGEN-ACTIVATOR INHIBITOR IN HUMAN NEOPLASTIC CELL-LINES, STUDIED WITH MONOCLONAL-ANTIBODIES
    ANDREASEN, PA
    CHRISTENSEN, TH
    HUANG, JY
    NIELSEN, LS
    WILSON, EL
    DANO, K
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1986, 45 (2-3) : 137 - 147
  • [5] PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 BIOSYNTHESIS AND MESSENGER-RNA LEVEL ARE INCREASED BY DEXAMETHASONE IN HUMAN FIBROSARCOMA CELLS
    ANDREASEN, PA
    PYKE, C
    RICCIO, A
    KRISTENSEN, P
    NIELSEN, LS
    LUND, LR
    BLASI, F
    DANO, K
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (08) : 3021 - 3025
  • [6] [Anonymous], 1988, LANCET, V2, P349
  • [7] CLONING AND EXPRESSION OF A CDNA CODING FOR A HUMAN MONOCYTE-DERIVED PLASMINOGEN-ACTIVATOR INHIBITOR
    ANTALIS, TM
    CLARK, MA
    BARNES, T
    LEHRBACH, PR
    DEVINE, PL
    SCHEVZOV, G
    GOSS, NH
    STEPHENS, RW
    TOLSTOSHEV, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (04) : 985 - 989
  • [8] ASHINOFUSE H, 1984, P SOC EXP BIOL MED, V176, P109
  • [9] ASTEDT B, 1987, Fibrinolysis, V1, P203, DOI 10.1016/0268-9499(87)90037-3
  • [10] AZNAR J, 1984, THROMB HAEMOSTASIS, V52, P196